Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03872557 · ClinicalTrials.gov registry record · NA
Modulating Glucose Tolerance With Dietary Tyrosine
A NA study, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT03872557 is a NA study that has completed, run by Columbia University. The registered enrollment target is 10 participants.
The verdict
NCT03872557, a NA study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
Metabolic or Bariatric surgery is an effective treatment for type 2 diabetes mellitus (T2DM) diabetes associated with obesity. There remain some questions about the biochemical mechanism that drive how these surgeries work to reverse hyperglycemia. In the proposed human studies, the investigators will test the hypothesis that the amino acid tyrosine is a key metabolite in regulating blood sugar levels and that manipulation of the amount tyrosine supplied by nutrition is able to achieve some of the metabolic benefits seen in the early post-surgical period following bariatric surgery. The central hypothesis is that that the tyrosine content of the meal challenge affects post-prandial intestinal and plasma dopamine and levodopa and L-3,4-dihydroxyphenylalanine (L-DOPA) levels, which, in turn, impact β-cell insulin secretion and glucose excursions. The investigators now propose to characterize the possible effects of manipulating dopamine and L-DOPA levels in the gut and plasma on glucose tolerance, insulin secretion, and insulin sensitivity in healthy volunteers with a range of body mass indexes (BMIs).
Interventions
- DIETARY_SUPPLEMENT Tyrosine (TYR) Supplementation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-08-07 |
| Est. Completion | 2020-01-24 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03872557
The ClinicalTrials.gov registry entry for NCT03872557 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tyrosine (TYR) Supplementation is the first listed.
NCT03872557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03872557 about?
NCT03872557 is a clinical study titled "Modulating Glucose Tolerance With Dietary Tyrosine". Metabolic or Bariatric surgery is an effective treatment for type 2 diabetes mellitus (T2DM) diabetes associated with obesity. There remain some questions about the biochemical mechanism that drive how these surgeries work to reverse hyperglycemia. In the proposed human studies, the investigators wi...
What is the current status of trial NCT03872557?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2019-08-07. Estimated completion is 2020-01-24.
What interventions are being tested in trial NCT03872557?
The interventions under investigation include: Tyrosine (TYR) Supplementation (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03872557?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.